


Discovery of 2-Alkyl-1-arylsulfonylprolinamides as 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 1 InhibitorsJianxin Yu,<sup>†,§</sup> Haiyan Liu,<sup>†,§</sup> Guangxin Xia,<sup>\*,†,‡</sup> Lin Liu,<sup>†,‡</sup> Zhenmin Xu,<sup>†</sup> Qian Chen,<sup>†</sup> Chen Ma,<sup>†</sup> Xing Sun,<sup>†</sup> Jiajun Xu,<sup>†</sup> Hua Li,<sup>†</sup> Ping Li,<sup>†</sup> Yufang Shi,<sup>†</sup> Bing Xiong,<sup>‡</sup> Xuejun Liu,<sup>†</sup> and Jingkang Shen<sup>\*,†,‡</sup><sup>†</sup>Central Research Institute, Shanghai Pharmaceutical Holding Co., Ltd., Building 5, 898 Ha Lei Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China<sup>‡</sup>State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Zhangjiang Hi-Tech Park, Shanghai 201203, China

## S Supporting Information


**ABSTRACT:** On the basis of scaffold hopping, a novel series of 2-alkyl-1-arylsulfonylprolinamides was discovered as 11 $\beta$ -hydroxysteroid dehydrogenase type 1 (11 $\beta$ -HSD-1) inhibitors. A representative compound **4ek**, obtained through SAR and structure optimization studies, demonstrates excellent in vitro potency against 11 $\beta$ -HSD-1 and dose-dependent in vivo inhibition of 11 $\beta$ -HSD-1 in a prednisone/prednisolone transformation biomarker study in mice.

**KEYWORDS:** metabolic syndrome, enzyme inhibitor, 11 $\beta$ -hydroxysteroid dehydrogenase type 1, sulfonamide, 2-alkylproline, prolinamide



Glucocorticoid receptor (GR) signaling plays a significant role in metabolic regulation, and defects in this signaling pathway have been implicated in the development of several phenotypes of metabolic syndrome.<sup>1</sup> GR signaling depends not only on the circulating cortisol levels but also on the intracellular production of cortisol through reduction of cortisone, the inactive glucocorticoid. The enzymes catalyzing the conversion between cortisone and cortisol are 11 $\beta$ -hydroxysteroid dehydrogenases (11 $\beta$ -HSDs). Among them, the type 1 isoform (11 $\beta$ -HSD-1), highly expressed in liver and adipose tissue, predominantly reduces cortisone to cortisol, and the type 2 isoform (11 $\beta$ -HSD-2), primarily expressed in kidney, oxidizes cortisol to cortisone. A potential role for 11 $\beta$ -HSD-1 inhibitors in metabolic syndrome, type 2 diabetes, and obesity has been established using transgenic mice.<sup>2–4</sup> On the basis of these findings, in recent years, 11 $\beta$ -HSD-1 is recognized as a promising target in metabolic disease.<sup>1–4</sup>

In the past decade, industrial and academic researchers have reported several classes of 11 $\beta$ -HSD-1 inhibitors with varied scaffolds, including sulfonamides (e.g., BVT-14225, **1a**), amides (e.g., PF-877423, **2**) (Figure 1), triazoles (e.g., Merck 544), and thiazolones (e.g., AMG-221).<sup>5–8</sup> In a phase II clinical trial, 11 $\beta$ -HSD-1 inhibitor INCB-13739 (structure undisclosed) significantly improved insulin sensitivity in type 2 diabetes patients who failed on metformin treatment and lowered triglyceride and cholesterol levels of patients with hyperlipidaemia and hypertriglyceridemia.<sup>9</sup> Currently, other examples such as PF-915275, MK-0916, and AZD-4071 are being evaluated in phase




**Figure 1.** 11 $\beta$ -HSD-1 inhibitors. Combining the arylsulfonyl moiety of **1a** or **1b** with the D-prolinamide moiety of PF-877423 (**2**) to discover 2-alkyl-1-arylsulfonylprolinamide **4a**.

I/II trials for potential oral treatment of metabolic diseases.<sup>10–12</sup>

We recently disclosed a new series of sulfonamides (e.g., **1b**, Figure 1) with high inhibitory activity against 11 $\beta$ -HSD-1, and compound **1b** showed a short duration of action in a pharmacodynamics (PD) model.<sup>13</sup> As part of our continuing

Received: June 11, 2012

Accepted: September 18, 2012

Scheme 1. Synthesis of Compounds 4a–g and 8a,b,e<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) CH<sub>3</sub>OH, SOCl<sub>2</sub>, reflux, 1 h. (b) 3-Chloro-2-methylbenzene-1-sulfonyl chloride, triethylamine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h. (c) NaOH, THF, CH<sub>3</sub>OH, H<sub>2</sub>O, rt, overnight. (d) RNH<sub>2</sub>, BOP-Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 6 h.

Table 1. In Vitro Potency of (*R*)-2-Methyl Prolinamides with Varied Amino Groups

Compound	R	h-11β-HSD-1 IC <sub>50</sub> <sup>a</sup> (nM)	m-11β-HSD-1 IC <sub>50</sub> <sup>a</sup> (nM)
4a		77	9.2% <sup>b</sup>
4b		6.4	13% <sup>b</sup>
4c		37% <sup>b</sup>	15% <sup>b</sup>
4d		1.5	64
4e		0.1	1.3
4f		35% <sup>b</sup>	18% <sup>b</sup>
4g		26	33% <sup>b</sup>


<sup>a</sup>Average of at least two replicates. <sup>b</sup>Percent inhibition at 100 nM, the mean of at least two experiments.

efforts to find novel and proprietary 11β-HSD-1 inhibitors, we combined the arylsulfonyl moiety of 1a or 1b with D-prolinamide moiety of 2 to form a new sulfonamide-D-prolinamide represented by 3 (Figure 1), which displayed only micromolar activity against human 11β-HSD-1 (h-11β-HSD-1) but poor liver microsome stability (HLM Clint 430

Table 2. In Vitro Potency of (*S*)-Enantiomers

Compound	R	h-11β-HSD-1 IC <sub>50</sub> <sup>a</sup> (nM)	m-11β-HSD-1 IC <sub>50</sub> <sup>a</sup> (nM)
8a		4300	ND
8b		1800	ND
8e		3.1	63

<sup>a</sup>Average of at least two replicates; ND, not determined.

Scheme 2. Synthesis of Compounds 4eb–el<sup>a</sup>















<sup>a</sup>Reagents and conditions: (a) (Boc)<sub>2</sub>O, Na<sub>2</sub>CO<sub>3</sub>, dioxane, H<sub>2</sub>O, rt, 0.5–2 h. (b) *trans*-4-Aminoadamantan-1-ol hydrochloride, BOP-Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, overnight. (c) CF<sub>3</sub>COOH, CH<sub>2</sub>Cl<sub>2</sub>, rt, 1–6 h. (d) ArSO<sub>2</sub>Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2–16 h.

μL/min/mg). In vitro metabolite identification studies indicated that the pyrrolidine ring of compound 3 was oxidized by HLM. We thought the substituent (e.g., alkyl) on the ring might be helpful to slow down the oxidation, so we first selected the commercially available (*R*)-α-methyl proline as a starting material and obtained compound 4a. Interestingly, 4a exhibited not only better HLM stability but also dramatically increased potency (IC<sub>50</sub> = 77 nM). Utilizing 4a as a starting point, we discovered and elaborated a series of 2-alkyl-1-arylsulfonylprolinamides as potent and selective 11β-HSD-1 inhibitors. Herein, we report the synthesis, structure–activity relationship (SAR), and optimization of this series.

2-Alkyl-1-arylsulfonylprolinamide derivatives have been prepared according to Schemes 1–3. The inhibitory activity of this series of compounds against h-11β-HSD-1 and mouse 11β-HSD-1 (m-11β-HSD-1) was determined by scintillation proximity assay (SPA) method,<sup>13–15</sup> and the results are listed in Tables 1–5. The selectivity over human 11β-HSD-2 (h-11β-HSD-2) and 3T3L1 cellular activity of some representative compounds was also tested.

As seen in Scheme 1, esterification of (*R*)-2-methylpyrrolidine-2-carboxylic acid (5) gave (*R*)-methyl 2-methylpyrrolidine-2-carboxylate (6). Typical sulfonylation of 6 and saponification of the resulting ester produced carboxylic acid

Table 3. In Vitro Potency and Liver Microsomal Stability of (R)-2-Methyl Prolinamides with Varied Arylsulfonyl Groups


Compound	Ar			
		h-11 $\beta$ -HSD-1 IC <sub>50</sub> <sup>a</sup> (nM)	m-11 $\beta$ -HSD-1 IC <sub>50</sub> <sup>a</sup> (nM)	HLM Clint ( $\mu$ L/min/mg protein)
4e		0.1	1.3	106
4eb		9.5	3% <sup>b</sup>	132
4ec		7.2	12% <sup>b</sup>	ND
4ed		3.3	146	134
4ee		8.4	125	ND
4ef		5.5	16% <sup>b</sup>	12
4eg		11	37% <sup>b</sup>	87
4eh		17	17% <sup>b</sup>	55
4ei		12	112	15
4ej		8.2	97	57
4ek		7.7	11	51
4el		3.9	31% <sup>b</sup>	148
17a		6.0	26% <sup>b</sup>	64

<sup>a</sup>Average of at least two replicates. <sup>b</sup>Percent inhibition at 100 nM, the mean of at least two experiments; ND, not determined.

7, followed by coupling with varied primary amines using bis(2-oxo-3-oxazolidinyl)phosphonic chloride (BOP-Cl) to yield target molecules **4a–g**. As summarized in Table 1, when a hydroxyl group is introduced to the 4-position of the cyclohexyl moiety, the potency toward h-11 $\beta$ -HSD-1 increased 12-fold (**4b** vs **4a**); however, the methoxyl derivative **4c** exhibited reduced activity (37% at a concentration of 100 nM), and all three compounds appeared to have very weak inhibition toward m-11 $\beta$ -HSD-1 (no more than 15% at a concentration of 100 nM). The adamant-2-yl-substituted **4d** and **4e** showed single-digit nanomolar and subnanomolar inhibition against human

enzyme (IC<sub>50</sub> = 1.5 and 0.1 nM); moreover, they were also potent inhibitors of rodent enzyme with IC<sub>50</sub> values of 64 and 1.3 nM, respectively. However, other bridged hydrocarbon substituents such as adamant-1-yl (**4f**) and 3-oxabicyclo[3.3.1]nonane (**4g**) led to poor activity versus rodent enzyme.

For comparison, using (S)-acid **9** instead of (R)-acid **5**, we synthesized (S)-form derivatives **8a**, **8b**, and **8e** (Scheme 1). As shown in Table 2, although the (S)-derivatives had lower activity than the corresponding (R)-derivatives **4a**, **4b**, and **4e**, the adamant-2-amino analogue **8e** exhibited high activity toward both human and rodent 11 $\beta$ -HSD-1.

Scheme 3. Synthesis of Compounds 17a–c<sup>a</sup>

<sup>a</sup>Reagents and conditions: (a) Triethylamine, CH<sub>2</sub>Cl<sub>2</sub>, rt, 2 h. (b) TMS-CF<sub>3</sub>, TBAF, THF, overnight. (c) NaOH, CH<sub>3</sub>OH, THF, H<sub>2</sub>O, rt, overnight. (d) 4-Aminoadamantane, BOP-Cl, DIPEA, CH<sub>2</sub>Cl<sub>2</sub>, 6 h.

Table 4. In Vitro Potency of Compounds 17a–c

compd	R <sup>1</sup>	h-11β-HSD-1 IC <sub>50</sub> <sup>a</sup> (nM)	m-11β-HSD-1 inh. at 100 nM <sup>b</sup> (%)
17a	OH	6.0	26
17b	CN	43	9.5
17c	COOMe	124	14

<sup>a</sup>Average of at least two replicates. <sup>b</sup>The mean of at least two experiments.

Table 5. In Vitro Potency of Compounds 18a,b

compd	R <sup>2</sup>	IC <sub>50</sub> <sup>a</sup> (nM)	
		h-11β-HSD-1	m-11β-HSD-1
4ek	–CH <sub>3</sub>	7.7	11
18a	–CH <sub>2</sub> CH <sub>3</sub>	16	164
18b	–CH <sub>2</sub> CH=CH <sub>2</sub>	33% <sup>b</sup>	87

<sup>a</sup>Average of at least two replicates. <sup>b</sup>Percent inhibition at 100 nM, the mean of at least two experiments.

Because h-11β-HSD-1 enzyme shares only about 79% homology with the mouse enzyme, it might be understandable that many 11β-HSD-1 inhibitors displayed species-dependent activity.<sup>5</sup> Some clinical candidates, such as INCB-13739 and PF-915275, lack potency against rodent enzyme, so in vivo pharmacokinetics (PK)/PD studies of these compounds require primate models.<sup>16</sup> In our series, cross-species potencies of adamant-2-yl derivatives 4d and 4e allowed us to employ rodent model.

It is reported that the adamantane group is prone to oxidation in living organism, which could cause a rapid elimination of the compound, so substituted adamantanes

Table 6. Profile of the Two Lead Compounds

	4e	4ek
in vitro assay		
h-11β-HSD-1 IC <sub>50</sub> <sup>a</sup>	0.1 nM	7.7 nM
m-11β-HSD-1 IC <sub>50</sub> <sup>a</sup>	1.3 nM	11 nM
h-HSD-2 IC <sub>50</sub> <sup>a</sup>	2.2 μM	>10 μM
selectivity ratio: h-HSD-2/h-11β-HSD-1 IC <sub>50</sub>	22000	>1300
m-11β-HSD-1 3T3L1 cellular IC <sub>50</sub> <sup>a</sup>	121 nM	11 nM
mice PK <sup>b</sup>		
CL [mL/(min kg)]	90	60
Vdss (L/kg)	0.51	0.63
iv t <sub>1/2</sub> (min)	14	14
po F (%)	9.1%	3.0%
ip F (%)	63%	33%
ip AUC <sub>0-t</sub> (ng h/mL)	597.0	939.0

<sup>a</sup>Average of at least two replicates. <sup>b</sup>Dosed iv (1 mg/kg), po (5 mg/kg), and ip (5 mg/kg) in male BALB/c mice; mean values over three mice.




Figure 2. In vivo inhibitory activity of 11β-HSD-1 in BALB/c mice by 4ek. Student's *t* test was used to compare the differences between the dosing group and the vehicle. \**P* < 0.05 vs vehicle.

have been used to prepare metabolically stable druglike molecules.<sup>17–19</sup> For example, introducing a hydroxyl group on the adamantane ring reduced Clog *P* and blocks metabolic soft spots.<sup>6</sup> In our test, hydroxylated adamant-2-yl derivative 4e possessed better stability in HLM than unsubstituted adamant-2-yl derivative 4d (HLM CL<sub>int</sub> of 4e vs 4d: 106 vs 499 μL/min/mg protein). Consequently, we next focused our attention on the derivatization of 4e.

Through the route depicted in Scheme 2, we synthesized more 4-amino-1-hydroxyl-adamantyl derivatives. (*R*)-1-(*tert*-Butoxycarbonyl)-2-methyl pyrrolidine-2-carboxylic acid 12, obtained from (*R*)-acid 5, coupled with *trans*-4-amino-adamantan-1-ol hydrochloride to provide intermediate 13. The target compounds (4eb–el) were then obtained by two successive steps from 13: deprotection and sulfonylation. As listed in Table 3, most of the aryl or heteroaryl groups maintained high binding affinities to human enzyme with single-digit nanomolar IC<sub>50</sub> values, but some of them lose rodent enzyme activity.

To extend the SAR of this series, we next explored the effect of the R<sup>1</sup> group on adamantane. Noticing 4-(1,1,1-trifluoro-2-hydroxypropan-2-yl)benzenesulfonamide reported in literature as a pharmacophore of 11β-HSD-1 inhibitors, we designed new

derivatives **17a–c** (Scheme 3 and Table 4).<sup>20</sup> As described in Scheme 3, sulfonylation of **6** afforded ketone **15**. Intermediate **16** was generated by treatment of **15** with (trifluoromethyl)-trimethylsilane (TMS-CF<sub>3</sub>)/tetra-*n*-butylammonium fluoride (TBAF) in THF and a following hydrolysis step. The target compounds were then produced via condensation of **16** with the 1-substituted 4-aminoadamantanes. As listed in Table 4, the potency against human enzyme of **17b** (R<sup>1</sup> = CN) or **17c** (R<sup>1</sup> = COOMe) decreases 7- or 20-fold as **17a** (R<sup>1</sup> = OH). However, all three compounds display only weak activity on rodent enzyme at a concentration of 100 nM.

To investigate the effect of R<sup>2</sup> group on the pyrrolidine, **4ek** analogues **18a** and **18b** were designed (Table 5). The synthesis of **18a** and **18b** is analogous to **4ek**, replacing starting material **5** in Scheme 1 with (R)-2-ethyl and (S)-2-allyl pyrrolidine-2-carboxylic acid.<sup>21</sup> As seen in Table 5, the methyl in the 2-position of pyrrolidine is superior to ethyl and allyl groups in terms of potency, but the 2-allyl analogue **18b** has higher affinity to rodent enzyme than human enzyme.

The potential for compounds **4e** and **4ek** to complete lead candidate criteria was further evaluated (Table 6). Both compounds were potent inhibitors of human and mouse 11 $\beta$ -HSD-1 and highly selective against human 11 $\beta$ -HSD-2. In the 3T3L1 cell-based assay, compound **4ek** was 11 times more potent than **4e**. In the mouse PK test, however, both **4e** and **4ek** showed high clearance, very short plasma half-life, and low oral bioavailability.

To look at the correlation between in vitro activity and in vivo inhibition, **4ek**, with higher cellular level activity than that of **4e**, was selected as a tool compound and progressed to an in vivo 11 $\beta$ -HSD-1 inhibition assay in mice. Because of the poor metabolic stability and low oral bioavailability of **4ek**, we at first selected intraperitoneal (ip) injection as administration route (Table 6, enhanced bioavailability after ip injection is 33%, 11 times of the po bioavailability). In this mechanistic biomarker study, normal mice were dosed with **4ek** (or vehicle) and then exogenous substrate prednisone, which transformed to prednisolone catalyzed by 11 $\beta$ -HSD1.<sup>22</sup> As illustrated in Figure 2, ip treatment of BALB/c mice with 3, 10, and 30 mg/kg **4ek** dose-dependently reduced the generation of prednisolone with inhibition of 34, 71, and 89%, respectively, and the corresponding plasma concentrations of **4ek** in mice were 28, 80, and 94 ng/mL.

In conclusion, we reported a new series of 2-alkyl-1-arylsulfonylprolinamides as human and rodent 11 $\beta$ -HSD-1 inhibitors. Primary optimization and SAR studies led to the discovering of compound **4ek**, which demonstrated potent and selective activity in vitro and in vivo inhibitory activity in a prednisone conversion experiment. Efforts to improve the PK profile of this series are under way and will be reported in the future.

## ■ ASSOCIATED CONTENT

### Supporting Information

Experimental procedures and characterization of new chemical entities. This material is available free of charge via the Internet at <http://pubs.acs.org>.

## ■ AUTHOR INFORMATION

### Corresponding Author

\*Fax: +86 21 50128885. E-mail: [xiagx@pharm-sh.com.cn](mailto:xiagx@pharm-sh.com.cn) (G.X.) or [jkshen@mail.shcnc.ac.cn](mailto:jkshen@mail.shcnc.ac.cn) (J.S.).

## Author Contributions

<sup>§</sup>These authors contributed equally.

## Funding

This work was supported by New Drug Creation Project of the National Science and Technology Major Foundation of China (project 2010ZX09401-404).

## Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

We are indebted to Prof. Ying Leng and Yu Shen, SIMM, for the molecular and cellular level 11 $\beta$ -HSDs assay.

## ■ ABBREVIATIONS

HSD, hydroxysteroid dehydrogenase; SAR, structure–activity relationship; HLM, human liver microsome; PK, pharmacokinetics; PD, pharmacodynamics; BOP-Cl, bis(2-oxo-3-oxazolidinyl)phosphonic chloride; TMS-CF<sub>3</sub>, (trifluoromethyl)trimethylsilane; TBAF, tetra-*n*-butylammonium fluoride; DIPEA, *N,N*-diisopropylethylamine

## ■ REFERENCES

- (1) Wang, M. Inhibitors of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 in antidiabetic therapy. *Handb. Exp. Pharmacol.* **2011**, *203*, 127–146.
- (2) Saiah, E. The role of 11 $\beta$ -hydroxysteroid dehydrogenase in metabolic disease and therapeutic potential of 11 $\beta$ -HSD1 inhibitors. *Curr. Med. Chem.* **2008**, *15*, 642–649.
- (3) Masuzaki, H.; Yamamoto, H.; Kenyon, C. J.; Elmquist, J. K.; Morton, N. M.; Paterson, J. M.; Shinyama, H.; Sharp, M. G.; Fleming, S.; Mullins, J. J.; Seckl, J. R.; Flier, J. S. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. *J. Clin. Invest.* **2003**, *112*, 83–90.
- (4) Kim, S. H.; Bok, J. H.; Lee, J. H.; Kim, I. H.; Kwon, S. W.; Lee, G. B.; Kang, S. K.; Park, J. S.; Jung, W. H.; Kim, H. Y.; Rhee, S. D.; Ahn, S. H.; Bae, M. A.; Ha, D. C.; Kim, K. Y.; Ahn, J. H. Synthesis and biological evaluation of cyclic sulfamide derivatives as 11 $\beta$ -hydroxysteroid dehydrogenase 1 inhibitors. *ACS Med. Chem. Lett.* **2012**, *3*, 88–93.
- (5) Barf, T.; Vallgård, J.; Emond, R.; Haeggstroem, C.; Kurz, G.; Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.; Engblom, L.; Edling, N.; Roenquist-Nii, Y.; Oehman, B.; Alberts, P.; Abrahmsen, L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11 $\beta$ -hydroxysteroid dehydrogenase type 1. *J. Med. Chem.* **2002**, *45*, 3813–3815.
- (6) Cheng, H.; Hoffman, J.; Le, P.; Nair, S. K.; Cripps, S.; Matthews, J.; Smith, C.; Yang, M.; Kupchinsky, S.; Dress, K.; Edwards, M.; Cole, B.; Walters, E.; Loh, C.; Ermolieff, J.; Fanjul, A.; Bhat, G. B.; Herrera, J.; Pauly, T.; Hosea, N.; Paderes, G.; Rejto, P. The development and SAR of pyrrolidine carboxamide 11 $\beta$ -HSD1 inhibitors. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2897–2902.
- (7) Hermanowski-Vosatka, A.; Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M.; Wu, T.; Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. 11 $\beta$ -HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. *J. Exp. Med.* **2005**, *202*, 517–527.
- (8) Véniant, M. M.; Hale, C.; Hungate, R. W.; Gahm, K.; Emery, M. G.; Jona, J.; Joseph, S.; Adams, J.; Hague, A.; Moniz, G.; Zhang, J.; Bartberger, M. D.; Li, V.; Syed, R.; Jordan, S.; Komorowski, R.; Chen, M. M.; Cupples, R.; Kim, K. W.; St. Jean, D. J.; Johansson, L.; Henriksson, M. A.; Williams, M.; Vallgård, J.; Fotsch, C.; Wang, M. Discovery of a potent, orally active 11 $\beta$ -hydroxysteroid dehydrogenase type 1 inhibitor for clinical study: Identification of (S)-2-



((1S,2S,4R)-bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(SH)-one (AMG 221). *J. Med. Chem.* **2010**, *53*, 4481–4487.

(9) Rosenstock, J.; Banarer, S.; Fonseca, V. A.; Inzucchi, S. E.; Sun, W.; Yao, W.; Hollis, G.; Flores, R.; Levy, R.; Williams, W. V.; Seckl, J. R.; Huber, R. The 11 $\beta$ -hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. *Diabetes Care* **2010**, *33*, 1516–1522.

(10) Courtney, R.; Stewart, P. M.; Toh, M.; Ndongo, M. N.; Calle, R. A.; Hirshberg, B. Modulation of 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ HSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11 $\beta$ HSD1 inhibitor. *J. Clin. Endocrinol Metab.* **2008**, *93*, 550–556.

(11) Feig, P. U.; Shah, S.; Hermanowski-Vosatka, A.; Plotkin, D.; Springer, M. S.; Donahue, S.; Thach, C.; Klein, E. J.; Lai, E.; Kaufman, K. D. Effects of an 11 $\beta$ -hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. *Diabetes Obes. Metab.* **2011**, *13*, 498–504.

(12) [http://www.astrazenecaclinicaltrials.com/other-drug-products/in\\_development\\_drugs/AZD4017/](http://www.astrazenecaclinicaltrials.com/other-drug-products/in_development_drugs/AZD4017/).

(13) Xia, G.; Liu, L.; Xue, M.; Liu, H.; Yu, J.; Li, P.; Chen, Q.; Xiong, B.; Liu, X.; Shen, J. Discovery of novel sulfonamides as potent and selective inhibitors against human and mouse 11 $\beta$ -hydroxysteroid dehydrogenase type 1. *Mol. Cell. Endocrinol.* **2012**, *358*, 46–52.

(14) Mundt, S.; Solly, K.; Thieringer, R.; Hermanowski-Vosatka, A. Development and application of a scintillation proximity assay (SPA) for identification of selective inhibitors of 11 $\beta$ -hydroxysteroid dehydrogenase type 1. *Assay Drug Dev. Technol.* **2005**, *3*, 367–375.

(15) Xia, G.; Xue, M.; Liu, L.; Yu, J.; Liu, H.; Li, P.; Wang, J.; Li, Y.; Xiong, B.; Shen, J. Potent and novel 11 $\beta$ -HSD1 inhibitors identified from shape and docking based virtual screening. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 5739–5744.

(16) Bhat, B. G.; Hosea, N.; Fanjul, A.; Herrera, J.; Chapman, J.; Thalacker, F.; Stewart, P. M.; Rejto, P. A. Demonstration of proof of mechanism and pharmacokinetics and pharmacodynamic relationship with 4'-cyano-biphenyl-4-sulfonic acid (6-amino-pyridin-2-yl)-amide (PF-915275), an inhibitor of 11 $\beta$ -hydroxysteroid dehydrogenase type 1, in cynomolgus monkeys. *J. Pharmacol. Exp. Ther.* **2008**, *324* (1), 299–305.

(17) Vielhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K. A.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1-[[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. *J. Med. Chem.* **2003**, *46*, 2774–2789.

(18) Patel, J. R.; Shuai, Q.; Dinges, J.; Winn, M.; Pliushchev, M.; Fung, S.; Monzon, K.; Chiou, W.; Wang, J.; Pan, L.; Wagaw, S.; Engstrom, K.; Kerdesky, F. A.; Longenecker, K.; Judge, R.; Qin, W.; Imade, H. M.; Stolarik, D.; Beno, D. W. A.; Brune, M.; Chovan, L. E.; Sham, H. L.; Jacobson, P.; Link, J. T. Discovery of adamantane ethers as inhibitors of 11 $\beta$ -HSD1: Synthesis and biological evaluation. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 750–755.

(19) Roche, D.; Carniato, D.; Leriche, C.; Lepifre, F.; Christmann-Franck, S.; Graedler, U.; Charon, C.; Bozec, S.; Doare, L.; Schmidlin, F.; Lecomte, M.; Valeur, E. Discovery and structure–activity relationships of pentanedioic acid diamides as potent inhibitors of 11 $\beta$ -hydroxysteroid dehydrogenase type I. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 2674–2678.

(20) Julian, L. D.; Wang, Z.; Bostick, T.; Caille, S.; Choi, R.; DeGraffenreid, M.; Di, Y.; He, X.; Hungate, R. W.; Jaen, J. C.; Liu, J.; Monshouwer, M.; McMinn, D.; Rew, Y.; Sudom, A.; Sun, D.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P. Discovery of novel, potent benzamide inhibitors of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 (11 $\beta$ -HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model. *J. Med. Chem.* **2008**, *51*, 3953–3960.

(21) Sakaguchi, K.; Yamamoto, M.; Watanabe, Y.; Ohfune, Y. *Tetrahedron Lett.* **2007**, *48*, 4821–4824.

(22) Male BALB/c mice (18–22 g, SIPPR-BK Lab Animal Co., Ltd.) were administered by intraperitoneal (ip) injection with vehicle (N-

methyl pyrrolidone:32%  $\beta$ -cyclodextrin:normal saline = 1:6:3/V:V:V) or with 3, 10, and 30 mg/kg of **4ek**. One hour after the vehicle or drug treatment, mice were dosed by iv injection with 3 mg/kg of prednisone. Venous blood samples were collected from the retinal vein 2 min later. Plasma prednisone, prolnisolone, and **4ek** levels were measured using the LC/MS/MS method (Waters Acquity UPLC system coupled to Applied Biosystems/Sciex API 4000 Q-Trap tandem mass spectrometry).